Exenatide
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
AstraZeneca · Phase 3 · Completed · Enrollment 119
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Exenatide once weekly (EQW ) | n/r | n/r | n/r | n/r |
| Dapagliflozin (DAPA) | n/r | n/r | n/r | n/r |
| EQW plus DAPA | n/r | n/r | n/r | n/r |
| Dapagliflozin plus Glucophage (MET ER) | n/r | n/r | n/r | n/r |
| Phentermine /Topiramate (PHEN/ TPM) ER | n/r | n/r | n/r | n/r |
Not shown
- Exenatide once weekly (EQW ): endpoint not reported
- Dapagliflozin (DAPA): endpoint not reported
- EQW plus DAPA: endpoint not reported
- Dapagliflozin plus Glucophage (MET ER): endpoint not reported
- Phentermine /Topiramate (PHEN/ TPM) ER: endpoint not reported